An Open Label, Phase 1 Study of SC‑004 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs SC 004 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 18 Jul 2017 Planned number of patients changed from 134 to 108.
- 18 Jul 2017 Planned End Date changed from 17 May 2021 to 15 Jun 2021.
- 18 Jul 2017 Status changed from not yet recruiting to recruiting.